Get the Stockscreener App
1.77
9.94%
0.16
After Hours:
1.78
0.01
+0.56%
iBio Inc stock is traded at $1.77, with a volume of 1.92M.
It is up +9.94% in the last 24 hours and down -12.81% over the past month.
iBio, Inc., a biotechnology company, provides product development and manufacturing services to clients, collaborators, and third-party customers in the United States and internationally. The company's services cover the stages of product selection, regulatory approval, and commercial product launch. Its lead therapeutic candidate is IBIO-CFB03 for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and other fibrotic diseases. It is also developing vaccine candidates for third parties. The company has collaboration agreements with ONEWAY Diagnostica; AzarGen Biotechnologies (Pty) Ltd; The Texas A&M University System; and Fraunhofer Center for Molecular Biotechnology, as well as strategic relationship with CC-Pharming Ltd. In addition, it offers a range of product and process development, analytical, and manufacturing services. iBio, Inc. is headquartered in New York, New York.
See More
Previous Close:
$1.61
Open:
$1.61
24h Volume:
1.92M
Relative Volume:
1.80
Market Cap:
$63.97M
Revenue:
$300.00K
Net Income/Loss:
$-24.74M
P/E Ratio:
-1.7594
EPS:
-1.006
Net Cash Flow:
$-19.19M
1W Performance:
+9.26%
1M Performance:
-12.81%
6M Performance:
+27.34%
1Y Performance:
+108.24%
1-Day Range:
$1.595
$1.775
1-Week Range:
$1.52
$1.775
52-Week Range:
$0.5562
$3.82
iBio Inc Stock (IBIO) Company Profile
Name
iBio Inc
Sector
Industry
Phone
302-355-0650
Address
600 Madison Avenue, Suite 1601, New York, NY
Compare IBIO vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
1.77 | 58.19M | 300.00K | -24.74M | -19.19M | -1.006 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-25 | Initiated | Oppenheimer | Outperform |
| Oct-17-25 | Initiated | Leerink Partners | Outperform |
| May-28-24 | Initiated | Chardan Capital Markets | Buy |
| Nov-29-21 | Initiated | JMP Securities | Mkt Outperform |
| Jan-22-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-26-20 | Initiated | Alliance Global Partners | Buy |
View All
iBio Inc Stock (IBIO) Latest News
Top iBio (IBIO) Competitors 2026 - MarketBeat
IBIO Stock Price, Quote & Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
iBio (NASDAQ: IBIO) substitutes SILV Fund after 876,340‑share transfer - Stock Titan
IBIO stock is soaring today after iBio's muscle-preserving drug receives approval for human trial in Australia - MSN
IBIO (IBIO) price target increased by 18.73% to 5.47 - MSN
iBio (IBIO) Receives Regulatory Clearance to Initiate Phase 1 Trial of IBIO-600 - Yahoo Finance
10 Best NASDAQ Growth Stocks to Buy and Hold Forever - Insider Monkey
IBIO (iBio Inc.) falls 2.37% today after Q1 2026 EPS lands slightly below consensus estimates.Revenue Guidance - Xã Châu Thành
IBIO (iBio Inc.) reports 77.8 percent year over year Q1 2026 revenue growth, shares edge higher.Growth Acceleration - Cổng thông tin điện tử Tỉnh Sơn La
iBio, Inc. 8-K/A Filing Details: Company Information, Address, and Stock Listing (April 8, 2026) - Minichart
iBio (IBIO) clarifies warrant expirations and advances IBIO-600 Phase 1 trial - Stock Titan
IBIO Stock Chart | IBIO INC (NASDAQ:IBIO) - ChartMill
LifeSci Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Chardan Capital Maintains IBio Inc(IBIO.US) With Buy Rating, Maintains Target Price $5 - 富途牛牛
Is iBio (IBIO) Stock Stable Now | Price at $2.17, Up 0.23%Aggressive Growth Stocks - Cổng thông tin điện tử tỉnh Tây Ninh
iBio Reports Q2 Fiscal Year 2026 Financial Results and Provides Corporate Update - ADVFN
iBio Inc. (IBIO) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Ibio (IBIO) Receives a Buy from Chardan Capital - The Globe and Mail
IBIO: Chardan Capital Maintains 'Buy' Rating with $5.00 Price Ta - GuruFocus
Ibio’s IBIO-600 cleared to enter clinic in Australia for obesity - BioWorld News
iBio Received Regulatory Clearance to Initiate Its Phase 1 Clinical Trial of IBIO-600 in Australia - Sahm
iBio receives approval to start phase 1 trial of IBIO-600 By Investing.com - Investing.com India
Is iBio (IBIO) Stock Risky Now | Price at $2.21, Down 1.12%Alpha Picks - Cổng thông tin điện tử tỉnh Lào Cai
iBio Receives Regulatory Clearance to Begin Phase 1 Trial of IBIO-600, a Long-Acting Anti-Myostatin Antibody for Obesity, in Australia 1 - Minichart
iBio, Inc. (IBIO) Stock Price, News, Quote & History - Yahoo! Finance Canada
iBio Advances to Clinical Stage With IBIO-600 Trial - TipRanks
iBio, Inc. (IBIO) stock price, news, quote and history - Yahoo Finance UK
IBIO Stock Is Soaring Today After iBio's Muscle-Preserving Drug Receives Approval For Human Trial In Australia - Stocktwits
Regulators clear iBio (NASDAQ: IBIO) to launch first-in-human IBIO-600 trial - Stock Titan
iBio receives approval to start phase 1 trial of IBIO-600 - Investing.com
Street Watch: Is iBio Inc a speculative investment2026 Investor Takeaways & Real-Time Volume Spike Alerts - baoquankhu1.vn
IBIO Technical Analysis | Trend, Signals & Chart Patterns | IBIO INC (NASDAQ:IBIO) - ChartMill
Aug Selloffs: Will iBio Inc benefit from green energy policiesInsider Selling & Real-Time Buy Zone Alerts - baoquankhu1.vn
FRA:0JV0 PB Ratio: 1.01 — 33% Below Median - GuruFocus
IBIO Should I Buy - Intellectia AI
iBio Inc. (0JV0.SG) cash flow - Yahoo Finance UK
Can iBio Inc stock double in the next yearQuarterly Performance Summary & Entry and Exit Point Strategies - baoquankhu1.vn
Insider List - GuruFocus
Insider Buying: Marc Banjak Acquires Additional Shares of iBio I - GuruFocus
iBio Inc Stock (IBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.77%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):